Retinal disease pharmaceutical sales will reach $17.38bn in 2020, a new DART study predicts
A new report by DART forecasts the overall world market for treating age-related macular degeneration (AMD or ARMD), diabetic retinopathy (DR) and other disorders of the retina will reach $17.38bn in 2020. That revenue forecast and others appear in Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF, published in July 2016.
This updated report provides the detailed analysis and opportunities in wet AMD, dry AMD and diabetic retinopathy (DR) sector. Many pharmaceutical companies are aiming to develop more effective drugs with different mechanism of action to treat wet AMD. At present there are no drugs in the market for dry AMD, although dry age-related macular degeneration (dAMD) is more common than wet AMD (wAMD). Currently, there are many drugs in the pipeline for the treatment of dry AMD. The breakthrough in the dry AMD sector is expected to happen in next 5 years, DART estimates.
There are unmet needs remaining in retinal diseases sector and pharmaceutical companies are aiming to meet these needs within the next ten years. Companies seek to improve upon the standard of care (SOC) treatment for wAMD, whilst developing new therapies for dry AMD and other retinal diseases such as diabetic retinopathy (DR) and retinal vein occlusion (RVO). The retinal disease overall market is expected to keep growing for the next 10 years as current promising pipeline candidates attain approvals. This report provides an analysis of this fast-growing market in 2015, as well as forecasting the prospects for revenue growth over the period 2016-2026.
Shruti Tayal, a pharmaceutical industry analyst in DART, said: “In 2015, Eylea is leading the therapeutic market of AMD and other retinal diseases. Avastin is challenging both Lucentis and Eylea for drug volume sales and price. DART expects the retinal market to reach revenues of $17.38bn with a CAGR of 10.2% by the end of 2020. Few products in the pipeline are waiting for approval to enter the wet AMD market. The status of dry AMD submarket may change due to the promising results shown by few drugs in the pipeline. In the second half of the forecast period, the market will face competition from generic drugs as branded drugs will lose patent exclusivity and there will be uptake of new products such as new combination therapies.”
This updated report shows 10-years revenue forecasts to 2026 at overall world market, disease submarkets, product (brand) and national market level. The study gives revenue predictions to 2026 for four therapeutic submarkets at world level:
- Wet age-related macular degeneration (wAMD)
- Dry AMD (dAMD)
- Diabetic retinopathy (DR)
- Other retinal diseases (grouped forecast).
The study also provides revenues and forecast of five prominent drugs to 2026: Lucentis, Eylea, Avastin, Visudyne and Jetrea.
Research, data and analyses cover activities of Roche, Novartis, Bayer, Regeneron, Allergan, Valeant and other developers, manufacturers and marketers of ophthalmic pharmaceuticals. Analyses cover leaders and other organisations for retinal medicines.
This new study also discusses R&D and commercial news, shows two interviews and predicts revenues to 2026 in 11 leading national markets. The work analyses the United States (US), EU5 (Italy, Spain, Germany, the UK and France), Japan, BRIC countries (Brazil, Russia, India and China), and the Rest of the World.
Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF adds to DART’s analyses on industries and markets in healthcare. Together those studies cover pharmaceuticals, diagnostics, medical devices, outsourced services and biotechnologies commercial potentials.